GLP-1.3 Nasal Spray

Product Details

GLP-1 (Glucagon-Like Peptide-1) is an endogenous peptide hormone belonging to the incretin family. It is composed of amino acid residues that enable interaction with specific receptor systems involved in glucose-related signaling pathways. Due to the rapid enzymatic degradation and short half-life of native GLP-1, structurally modified analogs such as liraglutide have been developed for extended stability in controlled research environments.

Liraglutide is a modified peptide analog of GLP-1, featuring an amino acid substitution at position 34, where lysine is replaced with arginine. This structural modification enhances resistance to enzymatic degradation and supports prolonged receptor interaction under experimental conditions.

Mechanism of Action

Liraglutide functions as a GLP-1 receptor agonist, binding selectively to GLP-1 receptors located on target cells. Upon receptor binding, it activates intracellular signaling pathways primarily mediated by cyclic adenosine monophosphate (cAMP).

This activation leads to downstream signaling cascades that regulate glucose-dependent biochemical pathways, including those associated with insulin signaling and glucagon modulation at the molecular level. Additionally, GLP-1 receptor activation is linked to delayed gastric signaling pathways and modulation of pancreatic islet cell activity through receptor-mediated mechanisms.

The compound is also studied for its interaction with pathways involved in cellular proliferation and differentiation, particularly within pancreatic beta-cell signaling systems. These processes are examined in terms of receptor activation and intracellular biochemical responses rather than outcome-based effects.

Chemical Properties of GLP-1

Research Applications

• GLP-1 Receptor Binding Studies

This compound is utilized in research focused on ligand-receptor interactions involving GLP-1 receptors. Studies analyze binding affinity, receptor activation, and downstream intracellular signaling pathways.

• cAMP Signaling Pathway Analysis

Liraglutide is examined for its role in modulating intracellular cAMP levels following receptor engagement. Research investigates how this signaling cascade influences enzyme activation and phosphorylation-dependent processes.

• Glucose Metabolism Pathway Research

The peptide is studied for its involvement in biochemical pathways associated with glucose regulation. Investigations focus on molecular signaling interactions rather than physiological outcomes.

• Pancreatic Islet Cell Signaling

Research explores how GLP-1 receptor activation influences signaling pathways within pancreatic islet cells, including mechanisms related to cellular communication and regulatory protein activity.

• Enzymatic Stability and Peptide Modification

Studies also evaluate how structural modifications impact resistance to enzymatic degradation. This includes examining peptide stability and receptor interaction duration under controlled laboratory conditions.

Why Choose BehemothLabz to Buy GLP-1 for Research

BehemothLabz provides research-grade GLP-1 manufactured under controlled laboratory conditions with strict quality assurance protocols. Each batch undergoes analytical verification to ensure consistency in molecular composition and purity.

Comprehensive documentation, including laboratory testing reports and sourcing transparency, supports reproducibility in experimental settings. BehemothLabz maintains a compliance-focused approach, supplying compounds intended strictly for laboratory-based investigation and analytical research

Disclaimer

GLP-1 is intended strictly for laboratory research and analytical purposes only. It is not intended for use in diagnostic procedures, therapeutic applications, or in vivo studies of any kind.

Any references to biochemical pathways, receptor interactions, or enzymatic processes are provided solely for informational and research-context purposes. This compound must be handled exclusively by qualified professionals in controlled laboratory environments in accordance with applicable regulations and safety guidelines.

Improper handling or use outside of controlled research settings is strictly prohibited.

References

• Ronn, J., Jensen, E. P., Wewer Albrechtsen, N. J., Holst, J. J., & Sorensen, C. M. (2017). Glucagon-like peptide-1 acutely affects renal blood flow and urinary flow rate in spontaneously hypertensive rats despite significantly reduced renal expression of GLP-1 receptors. Physiological reports, 5(23), e13503. https://doi.org/10.14814/phy2.13503
• Wang, Q., Chen, K., Liu, R., Zhao, F., Gupta, S., Zhang, N., & Prud’homme, G. J. (2010). Novel GLP-1 fusion chimera as potent long acting GLP-1 receptor agonist. PloS one, 5(9), e12734. https://doi.org/10.1371/journal.pone.0012734